Sponsor

Centre Hospitalier Regional Universitaire

France 2 Place Saint Jacques, Cs 51804, 25030 Besançon, France

About the sponsor

The sponsor funds studies in hepatocellular carcinoma, biliary tract carcinoma, glioblastoma, colorectal cancer, and melanoma, with strong interest in immune checkpoint inhibition, therapeutic cancer vaccines, and combinations with anti-angiogenic therapy or chemotherapy.

Hepatocellular carcinoma
Glioblastoma
Colorectal cancer
Cutaneous melanoma
Biliary tract carcinoma

Research activity also includes metastatic disease, unresectable tumors, and neoadjuvant or maintenance immunotherapy strategies.

About Specializations

Centre Hospitalier Regional Universitaire runs clinical trials in conditions such as Colorectal cancer metastatic, Anal squamous cell carcinoma, Biliary neoplasm, Colorectal cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

14 clinical trials

Biliary neoplasm

Recruiting

Study of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer

Registered drugNo placebo

Study of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Regorafenib with Cyclophosphamide, Capecitabine, and Aspirin for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Study on Regorafenib with Cyclophosphamide, Capecitabine, and Aspirin for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Anal squamous cell carcinoma

Recruiting

Study of Ezabenlimab and Drug Combination for Stage III Anal Cancer Treatment

Registered drugNo placebo

Study of Ezabenlimab and Drug Combination for Stage III Anal Cancer Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Colorectal cancer

Recruiting

Study on Indocyanine Green for Reducing Leakage in Colorectal Cancer Surgery Patients

Registered drugNo placebo

Study on Indocyanine Green for Reducing Leakage in Colorectal Cancer Surgery Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Indocyanine Green
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Renal failure+1

Recruiting

Study on Optimal Dose of Rabbit Anti-Human T-Lymphocyte Immunoglobulin and Mycophenolic Acid for Kidney Transplant Patients with Low Immunological Risk

Registered drugNo placebo